Abstract: The disclosure relates to the field of molecular biology, and in particular relates to the use of CXCL 14. According to the present invention, different antigen proteins are transferred to the surface of a DC cell by means of the chemotactic binding capacity of CXCL 14 and surface receptors of immune cells such as DC cells. A chemokine of CXCL14 can effectively induce the binding of an antigen molecule to a specific immune cell at the N-terminal of an antigen protein, such that the cross presentation effect of the antigen molecule is greatly enhanced, and CXCL14 can finally induce a stronger specific immune response of the antigen molecule.

Abstract: The chemotactic binding ability of CCL13 and an immune cell surface receptor such as DC cells is used to transport different antigenic proteins to the surface of the DC cells, the efficiency of phagocytosis, processing, and presentation of various antigenic proteins by the DC cells is improved, and the effect of preventing and treating related diseases of the antigenic proteins is enhanced. A T2 sequence is further added in an antigen, such that the immune effect can be enhanced.

Abstract: A composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor is provided. A method of preventing and/or treating cancer by administering a subject in need thereof the composition is provided. The combination of Sotagliflozin and a tyrosine kinase activity inhibitor may exhibit a synergistic inhibitory effect on tumors, and the efficacy of the combination is significantly better than that of a single drug.

Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.

Abstract: The present disclosure relates to the field of medical technology, and in particular to a composition and the use thereof in the manufacture of a medicament for treating cancer. The present disclosure provides a composition containing a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. The present disclosure shows through in vivo and in vitro anti-tumor tests that, based on the inhibitory effect of the tyrosine kinase activity inhibitor targeting VEGFR, EGFR and other receptor tyrosine kinases, the combination of Sotagliflozin and a tyrosine kinase activity inhibitor may exhibit a synergistic inhibitory effect on tumors, and the efficacy of the combination is significantly better than that of a single drug.

Abstract: The present disclosure relates to the field of medical technology, and in particular to use of a compound of formula I or a pharmaceutically acceptable salt, dimer or trimer thereof in the manufacture of a medicament for treating cancer. By testing the inhibitory effect on a variety of tumor cells, the results show that the compound of formula I has an inhibitory effect on tumor cells, with an IC50 of 40.77 ?M-182.5 ?M. In animal experiments, the compound of formula I shows a good inhibition effect on tumor volume, which is very significantly different from that of the solvent control group, p<0.05.

Abstract: The present invention relates to the field of medical technology, in particular to a composition for treating cancer and use and medicament thereof. The composition comprises an SGLT1 inhibitor and a VEGFR2 inhibitor. The present invention finds that SGLT1 interacts with VEGFR2 to promote the development and progression of tumors; the present invention also finds that a composition of a VEGFR2 targeting inhibitor and an SGLT1 inhibitor has a synergistic anti-tumor effect, and the composition of the VEGFR2 targeting inhibitor and the SGLT1 targeting inhibitor can be used in cancer treatment.

Abstract: Provided are a memory lymphocyte population, a culture medium, and a method for obtaining the memory lymphocyte population and a use of the same. The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO.